Email this article THE SERUMAL CONCENTRATION OF HBsAg IN PATIETS WITH CHB/HIV CO-INFECTION COMPARING WITH CHB MONO-INFECTION IN THE DIFFERENT PHASES OF NATURAL COURSE OF CHRONIC HEPATITIS В
Abstract
The prevalence and inclination to chronization of viral hepatitis B is 3 – 5 times higher in patients with HIV-infection than in HIV-negative ones. The natural clinical course of chronic hepatitis B (CHB) in patients with HIV has the features, connected with immune suppression and mutual influence of viruses. The quantitative determination of HBsAg allows the more precise monitoring of the natural course and the dynamics of treatment of patients with CHB but these features are little studied in patients with co-infection CHB/HIV.
In the work was presented the comparative analysis of the results of quantitative determination of the serumal HBsAg in 59 Patients with co-infection CHB/HIV and 60 ones with chronic hepatitis. At the study it was established, that in patients with CHB/HIV co-infection were observed the reliably higher qHBsAg levels than in HIV-negative ones both in whole and in each CHB phase that depends on the immune suppression degree and DNA level of hepatitis B virus.Keywords
Full Text:
PDFReferences
Management of hepatitis B and HIV coinfection Clinical Protocol for the WHO European Region (2011). WHO, 31. Available at: http://www.euro.who.int/__data/assets/pdf_file/0011/152012/e95792.pdf
Emiroglu, N. (2010). Viral hepatitis burden and policy directions in the European region of WHO: Summit Conference on Hepatitis B and C. 20.
Pol, S. (2013). Management of HBV in immunocompromised patients. Liver International, 33, 182–187. doi: 10.1111/liv.12055
Fattovich, G. (2003). Natural History and Prognosis of Hepatitis B. Seminars in Liver Disease, 23 (1), 047–058. doi: 10.1055/s-2003-37590
McMahon, B. J. (2004). The Natural History of Chronic Hepatitis B Virus Infection. Seminars in Liver Disease, 24, 17–21. doi: 10.1055/s-2004-828674
Lok, A. S. F., McMahon, B. J. (2007). Chronic hepatitis B. Hepatology, 45 (2), 507–539. doi: 10.1002/hep.21513
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. (2012). Journal of Hepatology, 57 (1), 167–185. doi: 10.1016/j.jhep.2012.02.010
Brunetto, M. R., Oliveri, F., Colombatto, P., Moriconi, F., Ciccorossi, P., Coco, B. et. al. (2010). Hepatitis B Surface Antigen Serum Levels Help to Distinguish Active From Inactive Hepatitis B Virus Genotype D Carriers. Gastroenterology, 139 (2), 483–490. doi: 10.1053/j.gastro.2010.04.052
Abdurahmanov, D. T. (2008). Kliniko-serologicheskie variantyi hronicheskoy HBV-infektsii. Klinicheskaya, 4 (1), 30–34.
Thompson, A. J. V., Nguyen, T., Iser, D., Ayres, A., Jackson, K., Littlejohn, M. et. al. (2010). Serum hepatitis B surface antigen and hepatitis B e antigen titers: Disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology, 51 (6), 1933–1944. doi: 10.1002/hep.23571
Jaroszewicz, J., Serrano, B. C., Wursthorn, K., Deterding, K., Schlue, J., Raupach, R. et. al. (2010). Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspective. Journal of Hepatology, 52 (4), 514–522. doi: 10.1016/j.jhep.2010.01.014
Chan, H. L.-Y., Wong, V. W.-S., Wong, G. L.-H., Tse, C.-H., Chan, H.-Y., Sung, J. J.-Y. (2010). A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology, 52 (4), 1232–1241. doi: 10.1002/hep.23803
Norah, A. T., Bzowej, N. H., Chang, K.-M., Hwang, J. P., Jonas, M. M., Murad, M. H. (2015). Guidelines for Treatment of Chronic Hepatitis B. Practice guideline. Hepatology, 1–23.
Who guidelines for the prevention, care and treatment of persons with chronic hepatitis b infection (2015). WHO guidelines, 1–166. Available at: http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf?ua=1&ua=1
Jaroszewicz, J., Reiberger, T., Meyer-Olson, D., Mauss, S., Vogel, M., Ingiliz, P. et. al. (2012). Hepatitis B Surface Antigen Concentrations in Patients with HIV/HBV Co-Infection. PLoS ONE, 7 (8), e43143. doi: 10.1371/journal.pone.0043143
Psevdos, J., Jong, H. K., Sharp, V. L. (2010). Predictors of loss hepatitis B surface antigen in HIV-infected patients. World Jornal of Gasroenterology, 16 (9), 1093–1096. doi: 10.3748/wjg.v16.i9.1093
Dudina, K. R., Znojko, O. O., Shut'ko, S. A., Klimova, E. A., Kuzina, L. E., Braginskij, D. M., Blohina, N. P., Jushhuk, N. D. (2011). Dinamicheskoe opredelenie kolichestvennogosoderzhaniya HBsAg v krovi v sopostavlenii s urovnem virusnoy nagruzki u patsientov s hronicheskoy HBV-monoinfektsiey. Russkiy zhurnal gastroenterologii, gepatologii, koloproktologii, 4, 37–42. Evailable at: http://www.gastro-j.ru/article/366-dinamicheskoe-opredelenie-kolichestvennogo-soderzhaniya-hbsag-v-krovi-v-sopostavlenii-s-urovnem-/show/full/
Puoti, M., Torti, C., Bruno, R., Filice, G., Carosi, G. (2006). Natural history of chronic hepatitis B in co-infected patients. Journal of Hepatology, 44, S65–S70. doi: 10.1016/j.jhep.2005.11.015
Martinot-Peignoux, M., Moucari, R., Leclere, L., Cardoso, A.-C., Carvalho, R., Boyer, N. et. al. (2010). 725 QUANTITATIVE HBSAG: A NEW SPECIFIC MARKER FOR THE DIAGNOSIS OF HBSAG INACTIVE CARRIAGE. Journal of Hepatology, 52, S282. doi: 10.1016/s0168-8278(10)60727-1
Seth, A. K. (2012). HBsAg Quantification in Clinical Practice. Journal of Clinical and Experimental Hepatology, 2 (1), 75–80. doi: 10.1016/s0973-6883(12)60084-x
Çelik, M., Arabul, M., Çekiç, C., Vatansever, S., İpek, S., Aslan, F., Ünsal, B. (2014). Clinical utility of hepatitis B surface antigen levels during the natural history and treatment of chronic hepatitis B infection. Gastroenterology Review, 3, 164–167. doi: 10.5114/pg.2014.43758
DOI: http://dx.doi.org/10.21303/2504-5679.2016.00222
Refbacks
- There are currently no refbacks.
Copyright (c) 2016 Larisa Moroz, Tetiana Melnyk
This work is licensed under a Creative Commons Attribution 4.0 International License.
ISSN 2504-5679 (Online), ISSN 2504-5660 (Print)